Tagged with BIA

Colombia Chief Operating Officer of Biopas, Pierre Faraldo, depicts the explosive growth the company has been achieving in the past 15 years to become one of Colombia’s success stories, with the ambitious objective to position itself among the Top regional pharmaceutical players in Latin America by 2020. How long have you…

Colombia Sunil Dhyani, general manager of IPCA in Colombia, a successful Indian firm continuously launching new molecules, shares his take on the company’s strategy decisions in Colombia, as well as wider opportunities in Latin America. How does Colombia differentiate itself from other markets in the region? “Colombia offers a great political…

Colombia Thomas Voigt, executive president of the German Chamber of Commerce in Colombia for seven years, discusses the gradual decentralisation of business in Colombia and the increasingly long-term commitment of German companies to this market. Can you give us a brief history of German Chamber of Commerce in Colombia? “German companies…

Colombia Francois Léger, recently appointed GM of Servier Colombia discusses his strategy to achieve the company’s ambitious growth plans to launch eight new products within the next three years. You have been appointed General Manager four months ago. Can you introduce yourself to our executive readership? Being originally from France and…

Colombia Jaime Calderon, CEO of IETS and with an extensive clinical background and deep understanding of the Colombian healthcare sector, shares IETS’ role in advancing the healthcare landscape while promoting superior standards and taking into account the concerns of the population and industry stakeholders. You were appointed CEO of IETS in…

Colombia Pfizer’s country manager and PEH Lead for Colombia & Venezuela, Diego Forero, shares his insights on the Colombian pharmaceutical market, his goals for Pfizer’s Colombian affiliate, and how Colombian operations fit into the group’s worldwide strategy. You just returned after eight years in the USA to lead Pfizer’s Colombian affiliate.…

Colombia Mariella Soto, QuintilesIMS’ country manager for Colombia, has been working in the pharmaceutical-related industry for over 25 years. She explains how her previous experience as a pharmaceutical executive is helping her to develop customer-focused services with QuintilesIMS and the company’s latest innovations in data mining and analysis. You have a…

Colombia Latin American Regional Head of MSN Labs, one of the most promising generics companies globally, Raman Wattamwar, speaks about the strength of the newly-formed affiliate in Colombia. He highlights Colombia’s optimal potential as a regional hub, the positive business environment for foreign generics players, as well as his overarching strategic…

Colombia Cristhian Salamanca, executive director of the Colombia-India Chamber of Commerce and Industry discusses the ties between both countries, the important role of the chamber in attracting Indian companies to Colombia, and the ease of doing business for pharmaceutical companies in the country after obtaining INVIMA approval. Could you please provide…

Colombia J&J Medical Devices regional VP Mircea Cubillos discusses the long-term vision for J&J in Colombia and Latin America. Moreover, he speaks about the company’s strategy for emerging markets, the importance of the collaboration with stakeholders and government actors in the medical devices sector, as well as his personal motivation to…

Colombia Executive president of ACEMI (La Asociación Colombiana de Empresas de Medicina Integral), Jaime Arias, discusses fostering the constructive participation of all actors in the Colombian healthcare sector and the challenges that need to be addressed to develop the sustainability of the healthcare system in the long-term. Could you explain ACEMI’s…

Colombia With over a decade as executive director of the Pharmaceutical Chamber of ANDI (The Colombian National Business Association), Rodrigo Arcila Gomez, shares his optimistic insights on the growth of the sector, the current status of pricing negotiations, his key achievements, and the need for a pharmaceutical landscape built on trust.…